New targetable oncogenes in non-small-cell lung cancer.

@article{Oxnard2013NewTO,
  title={New targetable oncogenes in non-small-cell lung cancer.},
  author={Geoffrey R. Oxnard and Adam F. Binder and Pasi Antero J{\"a}nne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 8},
  pages={
          1097-104
        }
}
The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 156 CITATIONS, ESTIMATED 60% COVERAGE

The evolving genomic classification of lung cancer

  • The Journal of pathology
  • 2014
VIEW 9 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 15 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 85 REFERENCES

RET, ROS1 and ALK fusions in lung cancer

  • Nature Medicine
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2012

Cancer genomics: technology, discovery, and translation.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 1 EXCERPT